Literature DB >> 12042814

CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation.

Ralf A Linker1, Mathias Mäurer, Stefanie Gaupp, Rudolf Martini, Bettina Holtmann, Ralf Giess, Peter Rieckmann, Hans Lassmann, Klaus V Toyka, Michael Sendtner, Ralf Gold.   

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). So far, immunological mechanisms responsible for demyelination have been the focus of interest. However, mechanisms regulating axon maintenance as well as glial precursor-cell proliferation and oligodendrocyte survival might also influence disease outcome. The cytokine ciliary neurotrophic factor (CNTF), which was originally identified as a survival factor for isolated neurons, promotes differentiation, maturation and survival of oligodendrocytes. To investigate the role of endogenous CNTF in inflammatory demyelinating disease, we studied myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) in CNTF-deficient and wild-type C57BL/6 mice. Disease was more severe in CNTF-deficient mice and recovery was poor, with a 60% decrease in the number of proliferating oligodendrocyte precursor cells (OPCs) and a more than 50% increase in the rate of oligodendrocyte apoptosis. In addition, vacuolar dystrophy of myelin and axonal damage were more severe in CNTF-deficient mice. These specific pathological features could be prevented by treatment with an antiserum against tumor necrosis factor-alpha, suggesting that endogenous CNTF may counterbalance this effect of TNF-alpha (ref. 7). Here we identify a factor that modulates, in an inflammatory environment, glial cell survival and is an outcome determinant of EAE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042814     DOI: 10.1038/nm0602-620

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  118 in total

Review 1.  Recent neuropathological findings in MS--implications for diagnosis and therapy.

Authors:  Hans Lassmann
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  Regulation of neurokine receptor signaling and trafficking.

Authors:  Neil M Nathanson
Journal:  Neurochem Int       Date:  2012-01-25       Impact factor: 3.921

Review 3.  No quiet surrender: molecular guardians in multiple sclerosis brain.

Authors:  Lawrence Steinman
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

4.  Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death.

Authors:  Alexander M Herrmann; Kerstin Göbel; Ole J Simon; Nico Melzer; Michael K Schuhmann; Max-Philipp Stenner; Andreas Weishaupt; Christoph Kleinschnitz; Stefan Bittner; Patrick Meuth; Olaf Stuve; Thomas Budde; Bernd C Kieseier; Heinz Wiendl; Sven G Meuth
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

Review 5.  Interactions of interleukin-1 with neurotrophic factors in the central nervous system: beneficial or detrimental?

Authors:  Wilma J Friedman
Journal:  Mol Neurobiol       Date:  2005-10       Impact factor: 5.590

6.  Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration.

Authors:  S Schilling; S Goelz; R Linker; F Luehder; R Gold
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

7.  Re-expression of a developmentally restricted potassium channel in autoimmune demyelination: Kv1.4 is implicated in oligodendroglial proliferation.

Authors:  Eva Herrero-Herranz; Luis A Pardo; Gertrude Bunt; Ralf Gold; Walter Stühmer; Ralf A Linker
Journal:  Am J Pathol       Date:  2007-06-28       Impact factor: 4.307

8.  Combinatorial Effect of Metformin and Lovastatin Impedes T-cell Autoimmunity and Neurodegeneration in Experimental Autoimmune Encephalomyelitis.

Authors:  Ajaib S Paintlia; Sarumathi Mohan; Inderjit Singh
Journal:  J Clin Cell Immunol       Date:  2013-06-30

Review 9.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 10.  [Multiple sclerosis: potential therapeutic options and update of ongoing studies].

Authors:  H Wiendl; H C Lehmann; R Hohlfeld; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.